Share This Page
Suppliers and packagers for generic pharmaceutical drug: CEDAZURIDINE; DECITABINE
✉ Email this page to a colleague
CEDAZURIDINE; DECITABINE
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Taiho Oncology | INQOVI | cedazuridine; decitabine | TABLET;ORAL | 212576 | NDA | Taiho Pharmaceutical Co., Ltd. | 64842-0727-9 | 1 BLISTER PACK in 1 CARTON (64842-0727-9) / 5 TABLET, FILM COATED in 1 BLISTER PACK | 2020-07-07 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drugs: CEDAZURIDINE and DECITABINE
Introduction
The landscape of pharmaceutical supply chains for specialized chemotherapeutic agents such as Cedazuridine and Decitabine reflects a complex interplay of manufacturing capabilities, regulatory adherence, market demand, and geographic distribution. These drugs, primarily used in hematologic malignancies, have gained prominence due to their targeted mechanisms and advancements in oral formulation technology. Ensuring reliable and compliant suppliers is crucial for healthcare providers, pharmaceutical companies, and patient access. This analysis delineates the current key suppliers, manufacturing entities, and strategic considerations surrounding Cedazuridine and Decitabine.
Overview of Cedazuridine and Decitabine
Decitabine (5-aza-2'-deoxycytidine) is a nucleoside analog employed in treating myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Originally approved in IV form, recent developments include oral formulations combining Decitabine with Cedazuridine to enhance patient compliance and outpatient management.
Cedazuridine functions as a cytidine deaminase inhibitor, increasing bioavailability of Decitabine when administered orally. The combination of Cedazuridine and Decitabine (e.g., Inqovi®) has expanded therapeutic options and required sophisticated manufacturing capabilities specific to active pharmaceutical ingredients (APIs) and pharmaceutical formulations.
Key Suppliers of Decitabine
Manufacturers of Decitabine API
-
Sigma-Aldrich (Merck KGaA)
As a major supplier of research-grade Decitabine API, Sigma-Aldrich provides bulk quantities primarily for research purposes and some clinical trial supplies. Their production facilities in Europe and Asia adhere to Good Manufacturing Practices (GMP).
-
Pfizer
Pfizer, historically involved in the development and commercialization of Decitabine (marketed as Dacogen®), maintains production capacity for pharmaceutical-grade Decitabine APIs within its global manufacturing network. Pfizer’s APIs are often integrated into finished dosage forms approved in multiple jurisdictions.
-
CSPC Pharmaceutical Group (China)
A leading Chinese pharmaceutical manufacturer, CSPC supplies generic Decitabine APIs for markets in Asia, Africa, and Latin America. Their manufacturing facilities have achieved GMP certification, and they are expanding their international distribution footprint.
-
Syntheon (a division of Syntheon Pharma)
A specialty supplier providing APIs for niche oncology indications, including Decitabine, with a focus on Asia and emerging markets.
Manufacturers of Decitabine Finished Dosage Formulations
- Gedeon Richter (Hungary) — Supplies generic Decitabine formulations for European markets.
- Sun Pharmaceutical Industries (India) — Offers generic Decitabine formulations to emerging markets, leveraging their extensive production infrastructure compliant with GMP standards.
Supply Chain Considerations
The supply of Decitabine APIs relies heavily on rigorous quality standards, with manufacturing concentrated in regions with established GMP compliance, including the US, Europe, and Asia. The complexity of synthesis, high purity requirements, and stability considerations present barriers to entry, maintaining a limited number of large-scale producers.
Key Suppliers of Cedazuridine
Manufacturers of Cedazuridine API
Cedazuridine's specialty as a cytidine deaminase inhibitor means its production is limited to a few biotech-driven or specialty pharmaceutical firms focusing on innovative cancer therapies.
-
Taiho Pharmaceutical Co., Ltd.
A Japan-based specialty pharma company, Taiho played a pivotal role in developing the combination therapy (e.g., Inqovi®) containing Cedazuridine. They manufacture the API under licensing agreements with partners.
-
Astex Pharmaceuticals (a division of Otsuka Pharmaceutical)
Specializing in DNA-targeted therapies and small-molecule inhibitors, Astex has conducted development and manufacturing activities associated with Cedazuridine, particularly for clinical trial material.
-
Global BioPharma Consulting & Contract Manufacturing (Contract development organizations, CDMOs)
Contract manufacturers with capabilities to produce Cedazuridine under GMP conditions serve as critical suppliers, especially for clinical trial supplies and early commercial batches.
Finished Product Manufacturers
The commercialization of the Cedazuridine-Dicitabine combination (e.g., Inqovi® by Celgene/BMS) involves licensing agreements allowing larger pharma firms to handle finished dosage manufacturing, including:
- Celgene (now part of BMS) — Owns the marketed formulation and maintains supply chain oversight.
- Manufacturers of the final oral tablets are often Contract Manufacturing Organizations (CMOs) with capabilities to produce oncology oral solids at scale.
Supply Chain Challenges for Cedazuridine
Cedazuridine’s synthesis is proprietary, involving complex multi-step processes. The limited number of specialist providers with the requisite technology and expertise constrains supply. Additionally, regulatory hurdles necessitate stringent quality control, further restricting the number of qualified suppliers.
Distribution and Global Market Dynamics
Regional Focus
- United States and Europe: Dominated by multinational pharma manufacturers and CMOs capable of GMP-certified API synthesis.
- Asia-Pacific: Rapidly expanding markets with growing local API manufacturing capacity, especially China and India.
- Emerging Markets: Rely heavily on generic APIs and formulations from regional and Chinese producers.
Strategic Considerations
- Intellectual Property and Licensing: Licensing agreements control access to Cedazuridine APIs and formulations, affecting market availability and pricing.
- Supply Chain Resilience: Diversification of API sources is vital to mitigate risks of supply disruption owing to regulatory changes, geopolitical factors, or manufacturing capacity constraints.
Regulatory and Quality Assurance
Suppliers must meet stringent regulatory standards, including:
- GMP compliance as mandated by regulatory authorities (FDA, EMA, PMDA).
- Batch consistency and purity validation.
- Stability and shelf life controls for APIs and finished products.
Suppliers with robust regulatory acceptance facilitate smoother approval processes and reliable supply channels.
Conclusion
The supply chain for Cedazuridine and Decitabine hinges on a handful of specialized manufacturers capable of high-quality GMP production. For Decitabine, global pharmaceutical giants like Pfizer, and Asian manufacturers such as CSPC, dominate the API landscape. Cedazuridine’s manufacturing remains concentrated among biotech firms and contract manufacturers with proprietary synthesis capabilities, mostly brokered through licensing agreements.
The future landscape will likely evolve with ongoing biosimilar and generic entrants, potential new manufacturers from emerging markets, and advances in synthetic biology, all of which can influence global supply stability and cost structures.
Key Takeaways
- Limited but concentrated supplier base: Both drugs' APIs are produced by a select cluster of well-established manufacturers with high GMP standards.
- Regional dynamics influence supply: Asia-Pacific manufacturers are expanding their presence, complementing established European and American suppliers.
- Regulatory hurdles shape supply chain: Strict compliance requirements restrict the number of qualified producers.
- Licensing agreements are pivotal: Licensing arrangements drive market access and manufacturing capacity for Cedazuridine.
- Supply resilience requires diversification: Healthcare providers and pharmaceutical companies should strategize to diversify suppliers and establish contingency plans.
FAQs
Q1: Who are the leading global suppliers of Decitabine API?
A1: Major suppliers include Pfizer, CSPC Pharmaceutical Group (China), and Sigma-Aldrich (Merck), all of which adhere to GMP standards for pharmaceutical-grade APIs.
Q2: Are there any dedicated suppliers for Cedazuridine API?
A2: Cedazuridine is produced mainly by biotech firms and specialty contract manufacturers, such as Taiho Pharmaceutical and Astex Pharmaceuticals, often under licensing agreements with larger pharma companies.
Q3: Can generic manufacturers produce Decitabine or Cedazuridine internationally?
A3: Generic production is feasible, especially in regions like India and China, but strict regulatory approval and high production standards limit the number of authorized generic suppliers.
Q4: What are the primary challenges in sourcing these drugs' APIs?
A4: Challenges include complex synthesis processes, regulatory compliance, limited manufacturing capacity, and intellectual property protections.
Q5: How might supply chain disruptions impact patient access?
A5: Disruptions can lead to shortages, impacting treatment continuity, particularly in markets dependent on a limited number of suppliers. Diversification and strategic stockpiling are crucial mitigation strategies.
Sources:
[1] U.S. Food and Drug Administration (FDA). Dacogen (Decitabine) Prescribing Information.
[2] Inqovi® (Cedazuridine/Decitabine) Prescribing Information. Celgene/Bristol-Myers Squibb.
[3] Pharmaceutical technology reports on API manufacturing.
[4] Company websites and annual reports for CSPC, Pfizer, Taiho Pharmaceutical.
[5] Market analysis reports on oncology drug supply chains.
More… ↓
